Roberto Salgado
Overview
Explore the profile of Roberto Salgado including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
200
Citations
11553
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loi S, Salgado R, Curigliano G, Romero Diaz R, Delaloge S, Rojas Garcia C, et al.
Nat Med
. 2025 Jan;
31(2):433-441.
PMID: 39838118
Patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC) have low pathological complete response (pCR) rates with neoadjuvant chemotherapy. A subset of ER+/HER2-...
2.
Takano E, Jana M, Lara Gonzalez L, Pang J, Salgado R, Loi S, et al.
PLoS One
. 2025 Jan;
20(1):e0317331.
PMID: 39792888
Triple negative breast cancers often contain higher numbers of tumour-infiltrating lymphocytes compared with other breast cancer subtypes, with their number correlating with prolonged survival. Since little is known about tumour-infiltrating...
3.
Garcia V, Gardecki E, Jou S, Li X, Shroyer K, Saltz J, et al.
J Pathol Inform
. 2024 Dec;
16:100411.
PMID: 39720416
Objective: With the increasing energy surrounding the development of artificial intelligence and machine learning (AI/ML) models, the use of the same external validation dataset by various developers allows for a...
4.
Vidal J, Tsiknakis N, Staaf J, Bosch A, Ehinger A, Nimeus E, et al.
EClinicalMedicine
. 2024 Dec;
78:102928.
PMID: 39634035
Background: Pathologist-read tumor-infiltrating lymphocytes (TILs) have showcased their predictive and prognostic potential for early and metastatic triple-negative breast cancer (TNBC) but it is still subject to variability. Artificial intelligence (AI)...
5.
Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, et al.
Nat Commun
. 2024 Nov;
15(1):10402.
PMID: 39613746
In HER2-positive breast cancer, clinical outcome and sensitivity to HER2-targeted therapies are influenced by both tumor and microenvironment features. However, we are currently unable to depict the molecular heterogeneity of...
6.
Bailey C, Pich O, Thol K, Watkins T, Luebeck J, Rowan A, et al.
Nature
. 2024 Nov;
635(8037):193-200.
PMID: 39506150
Extrachromosomal DNA (ecDNA) is a major contributor to treatment resistance and poor outcome for patients with cancer. Here we examine the diversity of ecDNA elements across cancer, revealing the associated...
7.
Dixon-Douglas J, Virassamy B, Clarke K, Hun M, Luen S, Savas P, et al.
NPJ Breast Cancer
. 2024 Oct;
10(1):94.
PMID: 39433772
The role of adaptive immunity in long-term outcomes in early breast cancer is increasingly recognised. Standard (neo)adjuvant chemotherapy can have adverse effects on immune cells. We conducted a retrospective longitudinal...
8.
Puttick C, Jones T, Leung M, Galvez-Cancino F, Liu J, Varas-Godoy M, et al.
Nat Genet
. 2024 Oct;
56(10):2121-2131.
PMID: 39358601
Disruption of the class I human leukocyte antigen (HLA) molecules has important implications for immune evasion and tumor evolution. We developed major histocompatibility complex loss of heterozygosity (LOH), allele-specific mutation...
9.
Nederlof I, Isaeva O, de Graaf M, Gielen R, Bakker N, Rolfes A, et al.
Nat Med
. 2024 Sep;
30(11):3223-3235.
PMID: 39284953
Immune checkpoint inhibition (ICI) with chemotherapy is now the standard of care for stage II-III triple-negative breast cancer; however, it is largely unknown for which patients ICI without chemotherapy could...
10.
Stover D, Salgado R, Savenkov O, Ballman K, Mayer E, Magbanua M, et al.
NPJ Breast Cancer
. 2024 Aug;
10(1):75.
PMID: 39169033
Association of stromal tumor-infiltrating lymphocytes (sTILs) with survival outcomes among patients with metastatic breast cancer (MBC) remains unclear. The primary objective was to evaluate the association of sTILs with progression-free...